WSJ: U.S. Drug Spending Climb
By PETER LOFTUS
April 14, 2016 12:01 a.m. ET
The new Hepatitis C drugs are accounting for much of this increase. Will it be worth it to have brought such headline risk to the industry?
GET IN TOUCH
By PETER LOFTUS
April 14, 2016 12:01 a.m. ET
The new Hepatitis C drugs are accounting for much of this increase. Will it be worth it to have brought such headline risk to the industry?